| |
|
2004 - Full Text and Abstracts
|
|
Top
|
|
Vol. 41
|
|
October, Supplement 7 October 2004, p1
|
|
Hematologic Malignancies and Complications: Focus on Emerging Treatments
|
|
October, Supplement 6 October 2004, p1
|
|
The Evolving Role of DNA Demethylating Agents in the Treatment of Sickle Cell Disease and Thalassemia
|
|
October, Supplement 5 October 2004, p1
|
|
Advances in Gaucher Disease: Therapeutic Goals and Evaluation and Monitoring Guidelines
|
|
October October 2004 No. 4, p255
|
|
Gene Therapy in Hematology
|
|
July July 2004 No. 3, p189
|
|
Chronic Lymphocytic Leukemia
|
|
April, Supplement 4 April 2004, p1
|
|
Targeted Therapies in Hematologic Malignancies
|
|
April, Supplement 3 April 2004, p1
|
|
New Perspectives in the Biology and Treatmentof Myeloproliferative Disorders
|
|
April, Supplement 2 April 2004, p1
|
|
Hemophilia Therapy Innovation: Development of an Advanced Recombinant Factor VIII by a Plasmin-/Albumin-Free Method
|
|
April April 2004 No. 2, p91
|
|
Erythrocyte Membrane Proteins and Their Diseases
|
|
January, Supplement 1 January 2004, p1
|
|
Seventh Novo Nordisk Copenhagen Symposium
|
|
January January 2004 No. 1, p1
|
|
Thrombotic Thrombocytopenic Purpura: Advances in Pathophysiology, Diagnosis, and Treatment
|
|
|
2003 - Full Text and Abstracts
|
|
Top
|
|
Vol. 40
|
|
October, Supplement 4 October 2003, p1
|
|
Thalidomide and the IMiDs in Multiple Myeloma
|
|
October October 2003 No. 4, p267
|
|
Genomics in Hematology
|
|
July, Supplement 3 July 2003, p1
|
|
Hemophilia Treatment Strategies: Balancing the Benefits and Risks
|
|
July July 2003 No. 3, p173
|
|
April, Supplement 2 April 2003, p1
|
|
Imatinib for Chronic Myeloid Leukemia
|
|
April, Supplement April 2003 No. 2, p1
|
|
April April 2003 No. 2, p105
|
|
January, Supplement 1 January 2003, p1
|
|
Therapeutic Approaches to Myeloproliferative Disorders
|
|
January, Supplement January 2003 No. 1, p1
|
|
January January 2003 No. 1, p1
|
|
|
2002 - Full Text and Abstracts
|
|
Top
|
|
Vol. 39
|
|
October, Supplement October 2002 No. 4, p1
|
|
October October 2002 No. 4, p217
|
|
July, Supplement July 2002 No. 3, p1
|
|
July July 2002 No. 3, p143
|
|
April, Supplement April 2002 No. 2, p1
|
|
April April 2002 No. 2, p73
|
|
January January 2002 No. 1, p1
|
|
|
2001 - Abstracts, References, and PDFs
|
|
Top
|
|
Vol. 38
|
|
October, Supplement 9 October 2001, p1
|
|
Current Issues in Hemostasis and Transfusion Medicine
|
|
October, Supplement 12 October 2001, p1
|
|
Treatment of Bleeding and Thrombotic Disorders
|
|
October, Supplement 11 October 2001, p1
|
|
Pathogen Inactivation Treatment of Platelet Components: Advancing From Theory to Clinical Practice
|
|
October, Supplement 10 October 2001, p1
|
|
Optimal Treatment of Malignancies Associated With Hyperuricemia
|
|
October October 2001 No. 4, p299
|
|
New Therapies of Sickle Cell Anemia and andbeta;-Thalassemia
|
|
July, Supplement 8 July 2001, p1
|
|
Implications of Signal Transduction Inhibition for the Treatment of Chronic Myeloid Leukemia
|
|
July, Supplement 7 July 2001, p1
|
|
New Strategies and Modalities for Optimal Patient Outcomes
|
|
July, Supplement 6 July 2001, p1
|
|
Modern Management of Acute Myeloid Leukemia
|
|
July July 2001 No. 3, p201
|
|
Therapies in Multiple Myeloma
|
|
April, Supplement 5 April 2001, p1
|
|
A Targeted Approach to Thrombosis: New Data, New Perspectives
|
|
April, Supplement 4 April 2001, p1
|
|
B-Domain Deleted Recombinant Factor VIII for the Treatment of Hemophilia A
|
|
April, Supplement 3 April 2001, p1
|
|
Multiple Myeloma Update: New Advances in Biology end Treatment
|
|
April April 2001 No. 2, p93
|
|
January, Supplement 2 January 2001, p1
|
|
Controversies in Polycythemia Vera
|
|
January, Supplement 1 January 2001, p1
|
|
Transfusion-Related Iron Overload in Sickle Cell Anemia
|
|
January January 2001 No. 1, p1
|
|
Acute Promyelocytic Leukemia
|
|
|
2000 - Abstracts, References, and PDFs
|
|
Top
|
|
Vol. 37
|
|
October, Supplement 7 October 2000, p1
|
|
Monoclonal Antibody Therapy for Hematologic Malignancies: Prospects for an Integrated Therapy Approach
|
|
October, Supplement 6 October 2000, p1
|
|
Anemia: Where Are We Now; Where Are We Going? Clinical Consequences and Treatment Benefits
|
|
October October 2000 No. 4, p315
|
|
Cytogenetics in Hematologic Malingies
|
|
July, Supplement 5 July 2000, p1
|
|
New Frontiers in Deep Vein Thrombosis Management
|
|
July July 2000 No. 3, p219
|
|
Idiopathic Thrombocytopenic Purpura
|
|
April, Supplement 4 April 2000, p1
|
|
Clinical Issues and Treatment Advances in Thrombocytopenia
|
|
April April 2000 No. 2, p111
|
|
BLood Group Antigens: Molecular Biology, Functions, and Clinical Applications
|
|
January, Supplement 3 January 2000, p1
|
|
Thalidomide Therapy for Hematologic Malignancies
|
|
January, Supplement 2 January 2000, p1
|
|
The Biologic Basis of Stem-Cell Therapy
|
|
January, Supplement 1 January 2000, p1
|
|
Splenctomy-sparing strategies for the treatment and long-term maintenance of chronic immune thrombocytopenic purpura
|
|
January January 2000 No. 1, p1
|
|
Acquired Aplastic Anemias
|
|
| |
|
